Gastric Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2034

Gastric Cancer Diagnostics Market Summary

Overview:

• The Gastric Cancer Diagnostics market is estimated at USD 2.0 billion in 2025 and is projected to reach USD 3.8 billion by 2034. Growth is anchored in the rising global incidence of gastric cancer, the high burden of Helicobacter pylori infection, and the growing role of biomarker and molecular testing in guiding targeted therapy and immunotherapy.
• The global Gastric Cancer Diagnostics market is growing at a CAGR of 7.31% during the forecast period from 2026 to 2034.
• By test type, the imaging tests segment dominated the Gastric Cancer Diagnostics market with a 55% share in 2025.
• By product type, the reagents and kits segment dominated the Gastric Cancer Diagnostics market with a share of 64% in 2025.
• By technology, the endoscopy segment dominated the Gastric Cancer Diagnostics market with a share of 34% in 2025.
• By end-user, the hospitals segment dominated the Gastric Cancer Diagnostics market with a share of 46% in 2025.
• North America dominated the global Gastric Cancer Diagnostics market revenue with a share of 40% in 2025, representing the highest regional market share globally.

Gastric cancer diagnostics comprises the tests, instruments, reagents, and kits used to screen for, diagnose, stage, and guide the treatment of gastric, or stomach, cancer. The category spans imaging tests, including upper gastrointestinal endoscopy, endoscopic ultrasound, computed tomography, magnetic resonance imaging, barium studies, and laparoscopy, and laboratory tests, including biopsy and histopathology, immunohistochemistry, molecular and biomarker testing, liquid biopsy, and blood tests. Diagnostic technologies include endoscopy and radiological imaging, histopathology and immunohistochemistry, in situ hybridization, polymerase chain reaction, next-generation sequencing, and liquid biopsy, supplied by companies such as Roche through Ventana, Agilent through Dako, Danaher through Leica Biosystems, Fujifilm and other endoscopy makers, and molecular and liquid biopsy specialists including Illumina, Guardant Health, and Natera. Biomarker testing, including HER2, PD-L1, microsatellite instability, Epstein-Barr virus, and claudin 18.2, increasingly guides targeted therapy and immunotherapy in gastric cancer. Testing is performed in hospitals, diagnostic and reference laboratories, academic and research institutes, and diagnostic centers. Over the past decade, the field has advanced from endoscopy and histopathology toward companion diagnostics, molecular profiling, and liquid biopsy that enable precision treatment. Driven by the rising incidence of gastric cancer, the high burden of Helicobacter pylori infection, and the growth of biomarker-guided therapy, gastric cancer diagnostics is an important and growing segment of oncology diagnostics.

Gastric Cancer Diagnostics Market Key Growth Drivers

• The rising global incidence of gastric cancer, one of the leading causes of cancer death worldwide, is expanding demand for diagnostic testing.
• The high global burden of Helicobacter pylori infection, a primary risk factor and recognized carcinogen, is driving screening and diagnosis.
• The growing role of biomarker and companion diagnostic testing, including HER2, PD-L1, microsatellite instability, and claudin 18.2, is expanding molecular testing to guide targeted therapy and immunotherapy.
• Expanding national and opportunistic screening programs, particularly in high-incidence countries in East Asia, are increasing early detection and diagnostic testing.
• Technological advances, including artificial intelligence-assisted endoscopy, molecular profiling, and liquid biopsy, are improving detection and precision diagnosis.
• Rising healthcare access, endoscopy capacity, and laboratory infrastructure in emerging markets are broadening the global demand for gastric cancer diagnostics.
• The convergence of rising incidence, biomarker-guided therapy, and expanding screening is expected to sustain steady growth in the global Gastric Cancer Diagnostics market through 2034.

Key Companies in Gastric Cancer Diagnostics Market

The competitive landscape is led by the following active developers and manufacturers of gastric cancer diagnostics instruments, reagents, and kits:

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Danaher Corporation
• Illumina, Inc.
• Guardant Health, Inc.
• Natera, Inc.
• FUJIFILM Holdings Corporation
• Siemens Healthineers AG

Factors Contributing to the Growth of the Gastric Cancer Diagnostics Market

Market Drivers

Rising Global Incidence of Gastric Cancer

The rising global incidence of gastric cancer is the foundational driver of gastric cancer diagnostics demand. According to the International Agency for Research on Cancer, gastric cancer is among the most common cancers and a leading cause of cancer death worldwide, with roughly one million new cases and hundreds of thousands of deaths each year, and incidence is particularly high in East Asia, Eastern Europe, and parts of South America. Every suspected and diagnosed case requires imaging, endoscopy, biopsy, and increasingly biomarker testing for diagnosis, staging, and treatment planning, generating sustained demand for diagnostics. The often late-stage presentation of gastric cancer and the resulting emphasis on earlier detection further increase testing. As the global burden of gastric cancer persists and diagnostic access expands, demand for gastric cancer diagnostics continues to grow, reinforcing sustained market growth throughout the forecast period.

High Burden of Helicobacter pylori Infection

The high global burden of Helicobacter pylori infection is a powerful driver of gastric cancer diagnostics demand. Helicobacter pylori, which infects a large share of the world's population, is the primary risk factor for gastric cancer and is recognized by the World Health Organization and the International Agency for Research on Cancer as a carcinogen. The infection drives chronic gastritis, peptic ulcer disease, and precancerous changes that can progress to gastric cancer, and its detection and eradication are central to gastric cancer prevention. Testing for Helicobacter pylori, including breath, stool, blood, and endoscopic tests, and the diagnosis and surveillance of associated precancerous conditions, generate substantial diagnostic demand. Rising awareness and screening for Helicobacter pylori, particularly in high-incidence regions, further increase testing. As the burden of Helicobacter pylori infection and associated gastric disease persists, its detection is expected to be an important driver of gastric cancer diagnostics demand across the forecast period.

Market Restraints

Despite steady momentum, the Gastric Cancer Diagnostics market faces material constraints. The late-stage presentation of gastric cancer and the absence of widespread, effective screening outside high-incidence countries limit early diagnosis and can constrain the diagnostic pathway. The invasive nature and cost of endoscopy, the primary diagnostic tool, together with the need for trained endoscopists and pathologists, constrain capacity, particularly in resource-limited settings. Reimbursement and cost-containment pressures constrain testing volumes and the adoption of newer, higher-cost molecular and liquid biopsy tests in some settings. Test standardization and access to biomarker testing vary across regions, and comprehensive molecular profiling and liquid biopsy can be costly and unevenly reimbursed. A shortage of trained specialists in endoscopy, pathology, and molecular diagnostics can constrain capacity and interpretation. Rigorous and evolving regulatory requirements for in vitro diagnostic and companion diagnostic devices, including the European In Vitro Diagnostic Regulation and Food and Drug Administration pathways, add cost and complexity to product development and market entry. Finally, uneven endoscopy and laboratory infrastructure, limited awareness, and affordability constraints in emerging markets can restrict access and adoption across parts of the forecast period.

Gastric Cancer Diagnostics Market Segment Analysis

The Gastric Cancer Diagnostics Market is segmented by Test Type (Imaging Tests, Laboratory Tests), Product Type (Reagents and Kits, Instruments), Technology (Endoscopy, Radiological Imaging, Histopathology and Immunohistochemistry, Molecular Diagnostics, Liquid Biopsy, Others), End-User (Hospitals, Diagnostic Laboratories, Diagnostic Centers, Academic and Research Institutes, Others), and Geography (North America, Europe, Asia-Pacific, Rest of World).

By Test Type

Dominant Subsegment: Imaging Tests.

The imaging tests segment accounted for 55% of the Gastric Cancer Diagnostics market in 2025. Imaging tests dominate because upper gastrointestinal endoscopy is the primary and definitive tool for the detection, visualization, and biopsy of gastric cancer, supported by endoscopic ultrasound, computed tomography, magnetic resonance imaging, barium studies, and laparoscopy for detection and staging. Endoscopy enables direct visualization of lesions and tissue sampling and is central to both screening in high-incidence countries and diagnosis worldwide, generating the largest share of diagnostic activity. Computed tomography and other imaging are essential for staging and treatment planning. The laboratory tests segment, including biopsy and histopathology, immunohistochemistry, molecular and biomarker testing, liquid biopsy, and blood tests, is a large and rapidly growing segment driven by the expansion of biomarker-guided therapy and molecular profiling, and it is central to precision treatment. Nonetheless, the central role of endoscopy and imaging in the detection, diagnosis, and staging of gastric cancer secures the leadership of the imaging tests segment across the forecast period, with laboratory and molecular testing growing strongly alongside.

By Product Type

Dominant Subsegment: Reagents and Kits.

The reagents and kits segment accounted for 64% of the Gastric Cancer Diagnostics market in 2025. Reagents and kits dominate because diagnostic testing consumes assay-specific reagents, antibodies, probes, stains, and kits for biopsy processing, histopathology, immunohistochemistry, in situ hybridization, molecular testing, and liquid biopsy, generating recurring, per-test demand that exceeds one-time instrument purchases in aggregate revenue. The growth of biomarker and companion diagnostic testing, including HER2, PD-L1, microsatellite instability, and claudin 18.2, expands reagent and kit consumption, and molecular and next-generation sequencing tests consume high-value consumables. Leading suppliers such as Roche through Ventana, Agilent through Dako, and molecular specialists generate substantial recurring reagent revenue. The instruments segment, including endoscopy systems, imaging equipment, immunohistochemistry and molecular analyzers, and sequencing platforms, represents important capital revenue and anchors reagent pull-through. Nonetheless, the continuous, volume-driven consumption of reagents and kits, tied directly to testing volume, secures the segment's leadership across the forecast period.

Gastric Cancer Diagnostics Market Region Analysis

Dominant Region: North America

North America accounted for 40% of the global Gastric Cancer Diagnostics market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects advanced diagnostic and oncology infrastructure, rapid adoption of biomarker and molecular testing, strong reimbursement, and the presence of leading manufacturers. The United States leads on the strength of advanced endoscopy, pathology, and molecular testing capacity, rapid adoption of companion diagnostics and liquid biopsy, and the presence of major players including Roche, Abbott, Thermo Fisher Scientific, Illumina, Guardant Health, and Natera. Although gastric cancer incidence is lower in North America than in East Asia, the region's high per-test value, advanced precision oncology, and rapid adoption of biomarker-guided therapy drive the largest revenue share. The regulatory environment is well established, with the Food and Drug Administration providing clearance and companion diagnostic pathways, including approvals tied to targeted therapies. Reimbursement supports oncology diagnostics, and strong research infrastructure further reinforces the market. This combination of infrastructure, precision oncology adoption, and manufacturer presence reinforces North America's leadership in the global market.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Gastric Cancer Diagnostics market. The region's elevated CAGR is driven by the highest global incidence of gastric cancer, large populations, established and expanding screening programs, and growing healthcare investment across China, Japan, South Korea, and Southeast Asia. East Asia bears the greatest burden of gastric cancer, and countries such as Japan and South Korea operate large endoscopic screening programs that generate substantial diagnostic volumes, while China's large population and rising diagnosis drive significant demand. Rising healthcare access, expanding endoscopy and laboratory capacity, and the growing availability of targeted therapies and companion diagnostics further increase testing. Both multinational and regional manufacturers, including endoscopy and molecular diagnostics companies, are expanding their presence. Government screening initiatives and rising awareness reinforce growth. The combination of the highest disease burden, large-scale screening, expanding access, and growing precision oncology positions Asia-Pacific as the highest-growth region over the forecast period.

Regional Commentary

North America

North America accounted for 40% of the global Gastric Cancer Diagnostics market revenue in 2025. The United States dominates the region on the strength of advanced diagnostic infrastructure, rapid adoption of biomarker and liquid biopsy testing, and the presence of leading manufacturers, while Canada contributes through its cancer care networks and Mexico expands access within its growing healthcare sector.

Europe

Europe represents a significant regional market, led by Germany, the United Kingdom, and France, and including high-incidence areas in Eastern Europe. Growth is supported by established endoscopy and pathology infrastructure, expanding biomarker testing, and the presence of major manufacturers, while the European In Vitro Diagnostic Regulation shapes product requirements and market access across the region.

Asia-Pacific

Asia-Pacific is the fastest-growing region and bears the highest global burden of gastric cancer, propelled by large-scale screening programs in Japan and South Korea, China's large population and rising diagnoses, and expanding healthcare access across the region. Growing endoscopy and molecular testing capacity and expanding access to targeted therapies broaden adoption.

Rest of World

The Rest of World region, spanning the Middle East, Africa, and South America, includes high-incidence areas in parts of South America and is an emerging growth frontier. A rising burden of gastric cancer, improving endoscopy and laboratory capacity, and expanding healthcare investment are broadening adoption, while investment in cancer diagnostics supports growth.

Gastric Cancer Diagnostics Market Competitive Landscape

The Gastric Cancer Diagnostics market is classified as Moderately Concentrated. A group of large diagnostics and imaging companies holds significant revenue across endoscopy, pathology, immunohistochemistry, and molecular testing, led by Roche through Ventana, Abbott, Thermo Fisher Scientific, Agilent through Dako, and Danaher through Leica Biosystems, while endoscopy leaders such as Fujifilm and imaging and molecular specialists including Siemens Healthineers, Illumina, Guardant Health, and Natera hold significant positions, and a field of specialized and regional players competes across the market. The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, spanning large imaging, pathology, and molecular diagnostics companies alongside specialized endoscopy, liquid biopsy, and regional players.
• Leading players: Roche through Ventana, Abbott, Thermo Fisher Scientific, Agilent through Dako, and Danaher through Leica Biosystems anchor the top tier, with Fujifilm, Siemens Healthineers, Illumina, Guardant Health, and Natera holding significant positions.
• Geographic reach: Leaders operate global commercial, manufacturing, and support networks, with strong positions across North America, Europe, and Asia-Pacific.
• Product portfolio strength: Top players hold broad portfolios spanning endoscopy, imaging, immunohistochemistry, molecular testing, next-generation sequencing, and liquid biopsy.
• Pipeline strength: Deep pipelines in companion diagnostics, molecular profiling, liquid biopsy, and artificial intelligence-assisted endoscopy and pathology.
• Strategic partnerships: Companion diagnostic collaborations with pharmaceutical companies, tied to targeted therapy approvals, shape the competitive landscape.
• M&A activity: Consolidation continues across molecular diagnostics, liquid biopsy, and pathology.
• Manufacturing capabilities: Large-scale reagent, antibody, and consumable manufacturing and instrument production are key competitive strengths and barriers to entry.
• Innovation focus: Companion and molecular diagnostics, liquid biopsy, artificial intelligence-assisted endoscopy and digital pathology, and novel biomarkers such as claudin 18.2.

Gastric Cancer Diagnostics Market Recent Developmental Activities

In 2024, the FDA approved zolbetuximab (Vyloy) for claudin 18.2-positive gastric and gastroesophageal junction cancer, alongside a claudin 18.2 immunohistochemistry companion diagnostic. Strategic significance: Establishes a new biomarker and companion diagnostic, expanding immunohistochemistry testing in gastric cancer.

In 2023 and 2024, immune checkpoint inhibitors such as pembrolizumab and nivolumab expanded in gastric and gastroesophageal cancer, reinforcing PD-L1 companion diagnostic testing. Strategic significance: Sustains demand for PD-L1 immunohistochemistry testing to guide immunotherapy.

Gastric Cancer Diagnostics Market Segmentation

Gastric Cancer Diagnostics Market by Test Type

• Imaging Tests (Upper Endoscopy, Endoscopic Ultrasound, CT Scan, MRI, Barium Swallow, Laparoscopy, Others)
• Laboratory Tests (Biopsy and Histopathology, Immunohistochemistry, Molecular and Biomarker Testing, Liquid Biopsy, Blood Tests, Others)

Gastric Cancer Diagnostics Market by Product Type

• Reagents and Kits
• Instruments

Gastric Cancer Diagnostics Market by Technology

• Endoscopy
• Radiological Imaging
• Histopathology and Immunohistochemistry
• Molecular Diagnostics (PCR and Next-Generation Sequencing)
• Liquid Biopsy
• Others

Gastric Cancer Diagnostics Market by End-User

• Hospitals
• Diagnostic Laboratories
• Diagnostic Centers
• Academic and Research Institutes
• Others

Gastric Cancer Diagnostics Market by Geography

• North America Gastric Cancer Diagnostics Market
• United States Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• Canada Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• Mexico Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• Europe Gastric Cancer Diagnostics Market
• Germany Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• United Kingdom Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• France Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• Italy Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• Spain Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• Rest of Europe Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• Asia-Pacific Gastric Cancer Diagnostics Market
• China Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• Japan Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• India Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• Australia Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• South Korea Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• Rest of the World (RoW) Gastric Cancer Diagnostics Market
• Middle East Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• Africa Gastric Cancer Diagnostics Market Size in USD million (2023-2034)
• South America Gastric Cancer Diagnostics Market Size in USD million (2023-2034)

Key Takeaways from the Gastric Cancer Diagnostics Market Report Study

• Market size analysis for the current gastric cancer diagnostics market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that have happened over the last 3 years.
• Key companies dominating the global gastric cancer diagnostics market.
• Various opportunities available for competitors in the gastric cancer diagnostics market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current gastric cancer diagnostics market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for gastric cancer diagnostics market growth in the future?

Target audience who can benefit from this gastric cancer diagnostics market report study

• Gastric Cancer Diagnostics product providers
• Research organizations and consulting companies
• Gastric Cancer Diagnostics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in gastric cancer diagnostics products
• Various end-users who want to know more about the gastric cancer diagnostics market and the latest technological developments in the gastric cancer diagnostics market.

Frequently Asked Questions:

Q1. What is the growth rate of the Gastric Cancer Diagnostics market?

The Gastric Cancer Diagnostics market is projected to expand at a CAGR of 7.31% during the forecast period of 2026-2034.

Q2. What is the market size of the Gastric Cancer Diagnostics market?

The Gastric Cancer Diagnostics market is estimated at USD 2.0 billion in 2025 and is projected to reach USD 3.8 billion by 2034.

Q3. Which region dominates the Gastric Cancer Diagnostics market?

North America dominated the Gastric Cancer Diagnostics market with a 40% share of global revenue in 2025, supported by advanced diagnostic and oncology infrastructure, rapid adoption of biomarker and liquid biopsy testing, supportive FDA pathways, and the presence of leading manufacturers. Asia-Pacific, which bears the highest global burden of gastric cancer, is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Gastric Cancer Diagnostics market?

The principal drivers are the rising global incidence of gastric cancer; the high burden of Helicobacter pylori infection; the growing role of biomarker and companion diagnostic testing, including HER2, PD-L1, microsatellite instability, and claudin 18.2; and expanding screening and early detection programs, reinforced by technological advances in endoscopy, molecular testing, and liquid biopsy, and expanding access in emerging markets.

Q5. Who are the major players in the Gastric Cancer Diagnostics market?

The major players include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Danaher Corporation, Illumina, Inc., Guardant Health, Inc., Natera, Inc., FUJIFILM Holdings Corporation, and Siemens Healthineers AG, among other active manufacturers profiled in the Competitive Landscape section. Roche through Ventana, Agilent through Dako, and Danaher through Leica Biosystems lead in pathology and companion diagnostics, while Fujifilm leads in endoscopy and Illumina, Guardant Health, and Natera in molecular and liquid biopsy testing.